lobbying_activities: 2467142

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2467142	852a4369-0347-47cc-bc7d-56ad78f140e1	Q2	MEHLMAN CONSULTING, INC.	284950	AARP, INC.	2020	second_quarter	PHA	S.1895 - Lower Health Care Costs Act including issues relating to drug pricing Older Americans Reauthorization Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019. House prescription drug price transparency legislation.	HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of	50000		0	0	2020-07-15T18:54:36.670000-04:00